Product 1 of 5
Prevagen
The memory supplement that faced a federal court
Regulatory & AdvertisingPrevagen became widely known through television advertising emphasizing memory and cognitive health. Its signature ingredient is apoaequorin, a protein originally identified in jellyfish.
Can taking apoaequorin meaningfully improve human memory?
The Federal Trade Commission and the New York Attorney General sued the marketer, Quincy Bioscience, in 2017. At a 2024 jury trial, jurors found that none of eight challenged statements was supported by competent and reliable scientific evidence. They found only two of the eight materially misleading, including the claim that Prevagen “reduces memory problems associated with aging.” The court then ordered the company to stop using all eight statements and later clarified that the order applies nationwide. It denied the state’s request for monetary penalties.
Quincy has appealed. The Second Circuit heard argument on February 26, 2026. We found no decision as of March 2026, the latest reporting available to us.
The existence of a clinical study, or an advertisement referring to one, does not establish that a supplement produces a clinically meaningful benefit.
Documented federal court action against specified advertising claims. The case is on appeal.
What reliable evidence demonstrates a meaningful memory benefit from the marketed product?